CTX310 Lipid Disorder: Phase 1 Trial Shows Prom...

By HEOR Staff Writer

November 10, 2025

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Rare Medications Coverage in the Netherlands: Price Reductions Required
Sanofi’s Rilzabrutinib Receives Orphan Designation for IgG4-Related Dis...
Most Expensive Drugs 2025: Trends and Implications in US Pharma Pricing
Efficacy of Ultomiris Pediatric TMA Treatment
Blinatumomab Benefit Assessment for ALL and Health Economics
Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS
Allopurinol Designated an Orphan Drug for Marfan Syndrome
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...
High Orphan Drug Prices Persist Despite Market Exclusivity Expiration
ZEVASKYN Gene Therapy: A Breakthrough for Recessive Dystrophic Epidermolysis ...